Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 2/20 | 0.91 |
| ▸ | PTAFR | P25105 | 1/20 | 0.81 |
| ▸ | CA2 | P00918 | 2/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.60 |
| ▸ | EPAS1 | Q99814 | 4/20 | 0.60 |
| ▸ | SOAT2 | O75908 | 1/20 | 0.60 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.60 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.59 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nectandrin A SCHEMBL29477323 | 1.00 | NR3C1 (0.91) | NR3C1PTAFRCA2HIF1AEPAS1 | |
| Nectandrin A SCHEMBL13506024 | 1.00 | NR3C1 (0.91) | NR3C1PTAFRCA2HIF1AEPAS1 | |
| Tetrahydrofuroguaiacin B SCHEMBL29484565 | 0.95 | NR3C1 (1.00) | NR3C1PTAFRCA2HIF1AEPAS1 | |
| Nectandrin B SCHEMBL12118675 | 0.95 | NR3C1 (1.00) | NR3C1PTAFRCA2HIF1AEPAS1 | |
| Nectandrin B SCHEMBL29351645 | 0.95 | NR3C1 (1.00) | NR3C1PTAFRCA2HIF1AEPAS1 | |
| Nectandrin B SCHEMBL30678749 | 0.95 | NR3C1 (1.00) | NR3C1PTAFRCA2HIF1AEPAS1 | |
| Nectandrin B SCHEMBL893163 | 0.95 | NR3C1 (1.00) | NR3C1PTAFRCA2HIF1AEPAS1 | |
| Nectandrin B SCHEMBL893437 | 0.95 | NR3C1 (1.00) | NR3C1PTAFRCA2HIF1AEPAS1 | |
| Tetrahydrofuroguaiacin B SCHEMBL12118597 | 0.95 | NR3C1 (1.00) | NR3C1PTAFRCA2HIF1AEPAS1 | |
| Nectandrin B SCHEMBL13506165 | 0.95 | NR3C1 (1.00) | NR3C1PTAFRCA2HIF1AEPAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2438923-B1 | COMPOSITION FOR PREVENTING OR TREATING OBESITY-RELATED DISEASES MEDIATED BY THE ACTIVATION OF AMPK AND INCLUDING 2,5-BIS-ARYL-3,4-DIMETHYLTETRAHYDROFURAN LIGNANS AS ACTIVE INGREDIENTS | UNIV CHOSUN IACF (KR) | 2015-03-18 | — | — | EP | claimed |
| CN-103936698-A | Composition For Preventing Or Treating Adiposity Or Metabolism Syndrome | UNIV CHOSUN IACF (KR) | 2014-07-23 | — | — | CN | claimed |
| CN-102481325-B | Composition for preventing or treating obesity-related diseases mediated by activation of AMPK, containing 2, 5-diaryl-3, 4-dimethyltetrahydrofurfuryl lignan as an active ingredient | UNIV CHOSUN IACF (KR) | 2014-05-28 | — | — | CN | claimed |
| US-20120083525-A1 | COMPOSITION FOR PREVENTING OR TREATING OBESITY-RELATED DISEASES MEDIATED BY THE ACTIVATION OF AMPK AND INCLUDING 2,5-BIS-ARYL-3,4-DIMETHYLTETRAHYDROFURAN LIGNANS AS ACTIVE INGREDIENTS | AMOREPACIFIC CORPORATION | 2012-04-05 | — | — | US | claimed |
| WO-2004096171-A1 | SKIN WHITENING COSMETIC COMPOSITION COMPRISING THE EXTRACT OF MACHILUS THUNBERGII AND THE COMPOUNDS ISOLATED THEREFROM | YEUNGNAM EDUCATIONAL FOUNDATION (KR) | 2004-11-11 | — | — | WO | claimed |
| WO-2024189607-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT | DIDENKO KIRILL (MX) | 2024-09-19 | — | — | WO | disclosed |
| EP-3747452-A1 | COMPOSITION FOR IMPROVING PHYSICAL STRENGTH OR ATHLETIC ABILITY, CONTAINING NUTMEG EXTRACT AS ACTIVE INGREDIENT | Korea Basic Science Institute (KR) | 2020-12-09 | — | — | EP | disclosed |
| CN-112040964-A | A composition containing Myristica fragrans Houtt extract as active ingredient for improving physical strength or athletic ability | 韩国基础科学研究院 | 2020-12-04 | — | — | CN | disclosed |
| US-20200360455-A1 | COMPOSITION FOR IMPROVING PHYSICAL STRENGTH OR ATHLETIC ABILITY, CONTAINING NUTMEG EXTRACT AS ACTIVE INGREDIENT | KOREA BASIC SCIENCE INSTITUTE (KP) | 2020-11-19 | — | — | US | disclosed |
| WO-2019151811-A1 | COMPOSITION FOR IMPROVING PHYSICAL STRENGTH OR ATHLETIC ABILITY, CONTAINING NUTMEG EXTRACT AS ACTIVE INGREDIENT | 한국기초과학지원연구원 | 2019-08-08 | — | — | WO | disclosed |
| EP-2812005-B1 | POLYHYDROXYLATED PENTACYCLIC TRITERPENE ACIDS AS HMG-COA REDUCTASE INHIBITORS | PRAIRIE BERRY EUROPE GMBH (DE) | 2018-06-27 | — | — | EP | disclosed |
| US-20150133552-A1 | POLYHYDROXYLATED PENTACYCLIC TRITERPENE ACIDS AS HMG-COA REDUCTASE INHIBITORS | Hans, Joachim (DE) | 2015-05-14 | — | — | US | disclosed |
| WO-1999020291-A2 | PHARMACEUTICAL GRADE GINKGO BILOBA | PHARMAPRINT, INC. (US) | 1999-04-29 | — | — | WO | disclosed |
| WO-1999021008-A1 | PHARMACEUTICAL GRADE GARLIC | PHARMAPRINT, INC. (US) | 1999-04-29 | — | — | WO | disclosed |
| EP-0900375-A1 | PHARMACEUTICAL GRADE BOTANICAL DRUGS | Pharmaprint, Inc. (US) | 1999-03-10 | — | — | EP | disclosed |
| WO-1997039355-A1 | PHARMACEUTICAL GRADE BOTANICAL DRUGS | PHARMAPRINT, INC. (US) | 1997-10-23 | — | — | WO | disclosed |
| US-5308867-A | Antiinflammatory and antishock agents; asthma | SANKYO COMPANY, LIMITED (JP) | 1994-05-03 | — | — | US | disclosed |
| EP-0371762-B1 | NEW PLATELET ACTIVATING FACTOR ANTAGONISTS, NAMED \"THE PHOMACTINS\", THEIR PREPARATION AND USE | Sankyo Company Limited (JP) | 1993-04-28 | — | — | EP | disclosed |
| US-5151529-A | Culture of fungus Phoma for antiinflammatory agents | SANKYO COMPANY, LIMITED (JP) | 1992-09-29 | — | — | US | disclosed |
| EP-0371762-A2 | New platelet activating factor antagonists, named \"the phomactins\", their preparation and use | Sankyo Company Limited (JP) | 1990-06-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083525-A1 | COMPOSITION FOR PREVENTING OR TREATING OBESITY-RELATED DISEASES MEDIATED BY THE ACTIVATION OF AMPK AND INCLUDING 2,5-BIS-ARYL-3,4-DIMETHYLTETRAHYDROFURAN LIGNANS AS ACTIVE INGREDIENTS | PRKAG1, PRKAG3, PRKAG2 | NR3C1 3543/4885PTAFR 1160/4885CA2 3553/4885 |
| US-20150133552-A1 | POLYHYDROXYLATED PENTACYCLIC TRITERPENE ACIDS AS HMG-COA REDUCTASE INHIBITORS | HMGCR, PTAR1, CYP46A1 | NR3C1 415/4885PTAFR 106/4885CA2 3267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.